Emerging Technology Platforms
Method Development and Biosafety Support for Next-Generation Therapeutics
With the rapid advancement of mRNA, exosomes and other novel therapeutic and delivery technologies, traditional testing methods and quality control systems are facing unprecedented challenges.
With forward-looking technological layout and profound expertise in methodology, HyQure BioTech has established comprehensive testing and method development capabilities for emerging technology platforms, providing solid support for innovative therapeutics from proof of concept to clinical trials and future commercialization.
Why Do Emerging Technologies Require A "Method Development-Driven" Testing Strategy?
Unlike mature biopharmaceuticals, emerging technology platforms typically face the following common challenges:
Lack of mature and universally recommended testing methods by regulations
The product forms are complex, and the definition of quality attributes is still evolving.
Existing standard methods are difficult to adapt directly.
Regulatory agencies such as the FDA and EMA are placing greater emphasis on methodological soundness and scientific rationale.
Against this backdrop, "whether or not one possesses detection capabilities" is no longer the key factor; rather, "whether or not one has the ability to develop appropriate methods" is the decisive factor.
HyQure BioTech philosophy of method development
HyQure BioTech regards **method development** as a core capability supporting emerging technologies, rather than merely a pre-detection step:
Method Development as the Foundation
This philosophy enables HyQure BioTech to provide customers with truly practical and applicable testing and analysis solutions in areas where the technology is not yet fully mature.
With the product characteristics , rather than simply applying existing methods.
This philosophy enables HyQure BioTech to provide customers with truly practical and applicable testing and analysis solutions in areas where the technology is not yet fully mature .
Emerging Technology Platforms Covered.
Supported Emerging Modalities
mRNA and mRNA vaccines/therapeutic products
01
Exosomes and extracellular vesicle products
02
New delivery system related products
03
Other novel biotechnology platforms for which there are no mature detection paradigms
04
Core Competency 1
Method Development & Customized Analytics
- Construction of a Quality Attribute Analysis Approach for New Products.
- Exploratory development and optimization of detection methods.
- Methodological Feasibility and Robustness Assessment.
- Adaptation and conversion of methods to registration-level applications.
- Product-specific methods development.
- We have an experienced interdisciplinary methods development team (molecular biology, virology, biosafety, analytical science).
- A Deeper Understanding of the FDA's Focus on the "Scientific Rationality" of New Technological Methodologies.
- Multiple projects have had their methodological acceptability verified through FDA technical communication and review.
Core Competency 2
Biosafety & Quality Control for Emerging Technologies
Building on its methodology development, HyQure BioTech provides progressively comprehensive biosafety and quality control support for emerging technology platforms.
Products Description
Biosafety risk identification and assessment
01
Design of Safety Detection Strategies for Microorganisms and Viruses
02
Analysis of process-related impurities and residues supports
03
Data Integration and Risk Assessment Report
04
TPreparation of technical documents to support regulatory communication
05
Core Competency 3
Regulatory-aligned Method Strategy
● The need for IND/BLA applications should be considered during the methodology development phase.
● Supports dual US-China reporting and FDA technical communication.
● Clearly distinguish between exploratory methods and registration-level methods.
● This provides a clear path for subsequent method validation and release testing.
● Extensive experience in FDA projects provides clear "boundary conditions" for method design.
● To explain the scientific validity of methods using regulatory language , rather than just experimental results.
HyQure BioTech Core Strengths in Emerging Technology Platforms
Why HYQURE Biotech
Method development-driven technical capabilities
● Not relying on a single mature technology route
● Capable of handling complex scenarios where "no ready-made methods are available".
● Support the continuity between early-stage exploration and later-stage application for innovative therapies
01
Extensive regulatory and FDA experience
● 1 2 0+ successful IND/BLA project experience
● 50+ overseas application cases , covering multiple new technology pathways
● Familiar with the FDA's "cautious but open" review logic for emerging technologies.
02
Cross-platform integration capabilities
● It can synergize with platforms such as antibodies, CGT, vaccines, and viral vectors.
● Supports combined and cross-technology products
03
Project management and delivery capabilities
● PMP Project Management Team
● Highly customized project execution and rapid response mechanism
04
Applicable Development Stage
Proof of Concept (PoC)
Preclinical research
IND Application Preparation
Clinical Phase Method Optimization
Laying the methodological foundation for future commercialization